Trials / Unknown
UnknownNCT03622177
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection : a Prospective Cross-sectional Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (estimated)
- Sponsor
- ANRS, Emerging Infectious Diseases · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Interleukin33 organize local immune reactions, especially at epithelial barriers. ST2 is the IL33 receptor. The sST2 rate is higher for patient living with HIV and is an independent predictable factor of mortality. Interleukin33 induce tissue Treg ST2+ lymphocytes proliferation and amphireguline production. Amphireguline is member of epithelial growth factors family, which contributes to tissue repair, and fibrose. Amphireguline also helps immunosuppressives functions. Targetting amphiregulin for people living with HIV who has poor restauration of LTCD4+ could be a future therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | biopsie | Additional colorectal mucosal biopsies during rectoscopy or colonoscopy |
| BIOLOGICAL | blood drawn | Additional blood drawn by venepuncture |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2019-09-01
- Completion
- 2023-09-01
- First posted
- 2018-08-09
- Last updated
- 2018-08-09
Source: ClinicalTrials.gov record NCT03622177. Inclusion in this directory is not an endorsement.